Chimeric Antigen Receptor News and Research

RSS

New CAR T therapy could be more effective and less toxic against neuroblastoma

CAR T therapy has transformed the treatment for leukemia. Regrettably, the therapy is not effective enough to treat solid tumors, like neuroblastoma.

22 Jan 2021

Researchers create molecular ON-OFF switches to regulate CAR T cell activity

CAR T cells are a breakthrough class of effective but often toxic cancer therapies. To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug.

7 Jan 2021

Researchers identify a vital protein needed to regulate anti-tumor immune response

Scientists from The University of Texas MD Anderson Cancer Center have identified a protein known as NF-kappa B-inducing kinase (NIK).

5 Jan 2021

Combination method can boost immunotherapy for breast cancer

According to a new study performed by scientists from the University of North Carolina, stimulating an immune signaling pathway, which is best known for combating bacterial and viral infections, can increase the potential of genetically engineered T cells to remove breast cancer in mice.

4 Jan 2021

Study: CAR T cell therapy is a safe, effective therapy for high-risk large B-cell lymphoma

A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.

8 Dec 2020

Researchers target pathogenic T cells that could lead to new immunotherapy treatments

According to a new study, a novel T cell genetically engineered by scientists from The University of Arizona Health Sciences can target and attack pathogenic T cells that are responsible for causing Type 1 diabetes. These latest findings may result in new immunotherapy therapies.

7 Dec 2020

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

7 Dec 2020

New method to improve preclinical evaluation of CAR-T cell therapies

Ludwig Cancer Research scientists have developed a method to significantly improve the preclinical evaluation of chimeric antigen-receptor (CAR) T cell therapies.

9 Nov 2020

Novel approach based on microfluidic technology to fight cancer

CAR-T biotherapeutics company Carina Biotech and researchers at the University of South Australia have developed a novel approach based on microfluidic technology to "purify" the immune cells of patients in the fight against cancer.

21 Oct 2020

Researchers identify drug that could overcome tumor resistance

Scientists have discovered that a drug that may make some melanoma tumors perceptible to the immune system, enabling them to be better targeted.

15 Oct 2020

Virus-mimicking drugs may overcome immunotherapy resistance in tumors

Researchers at the UCLA Jonsson Comprehensive Cancer Center have found that a drug that activates the body's natural defenses by behaving like a virus may also make certain stealthy melanoma tumors visible to the immune system, allowing them to be better targeted by immunotherapy.

15 Oct 2020

Immunotherapy using CAR NKT cells shows promise for treating solid tumors

Natural killer T (NKT) cells, a type of immune cells known for their potent anti-cancer properties in murine tumor models, have been developed into a novel form of immunotherapy to treat patients with cancer.

14 Oct 2020

Treatment using immune system T cells preserves vision of mice with retinoblastoma

A treatment that uses immune system T cells, combined with an immune-boosting drug packaged in an injectable gel, was found to preserve the vision of mice implanted with tissue from a human eye cancer known as retinoblastoma.

13 Oct 2020

Memory training for the immune system

After an infection of the human body with a pathogen, a cascade of reactions will usually be set into motion.

29 Sep 2020

Researchers develop CAR-T cell therapy based on TCR signal transduction

The T cell receptor (TCR) is a key receptor that is responsible for detecting tumor antigens in T cells.

4 Aug 2020

Clinical trial shows CAR-T cell therapy can be used for treating Hodgkin lymphoma

CAR-T cell therapy, which attacks cancer cells using a person's reprogrammed immune cells, has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial led by researchers at UNC Lineberger Comprehensive Cancer Center and Baylor College of Medicine in Houston.

24 Jul 2020

New approach is more effective in treating certain blood cancers

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient's immune system to attack cancer.

24 Jul 2020

New, promising CAR T cell therapy results in exceptional patient recovery

In a clinical trial evaluating a novel immunotherapy option for cancer treatment, a child with rhabdomyosarcoma, a form of muscle cancer, that had spread to the bone marrow, showed no detectable cancer following treatment with chimeric antigen receptor (CAR) T cells that were engineered to target the HER2 protein on the surface of cancerthe cells.

16 Jul 2020

Study shows engineered natural killer immune cells can directly kill tumor cells

According to a study, researchers have successfully designed natural killer immune cells that destroy head and neck tumor cells in mice.

8 Jul 2020

CAR T Cell Therapy: Potential For Considerable Savings

CAR T cell therapy is a new and, in some cases, highly effective form of immunotherapy to treat certain types of cancer of the blood and lymph system.

24 Jun 2020